Timing and prognosis of brain metastasis development in breast cancer by subtype
Clicks: 9
ID: 329583
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.4
/100
9 views
8 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #52 of 62 articles by views in jnci cancer spectrum
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Limited data on the timing of brain metastases development and subsequent prognosis by breast cancer subtype exist. We retrospectively evaluated a cohort of 671 patients diagnosed with brain metastases secondary to breast cancer. Patients were categorized by subtype: human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive/HER2-negative (HR+/HER2-), and triple negative (TN). We found significant heterogeneity in the timing of brain metastases development and subsequent prognosis by subtype. Patients with HR+/HER2- disease developed brain metastases later in the disease course compared to patients with HER2+ and TN disease. Median overall survival following brain metastases diagnosis was shortest in patients with TN disease; however, among all subtypes, overall survival decreased with an increasing number of systemic therapies prior to the diagnosis of brain metastases. Altogether, these findings may inform differential timing of brain-directed screening imaging in patients with breast cancer.
| Reference Key |
openalex_W7214106058
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Narmeen S Rashid, Nayan Lamba, Ivy Ricca, Marciana Johnson, Paul J. Catalano, Shyam Kumar Tanguturi, Rifaquat Rahman, Daphne A Haas-Kogan, Patrick Y Wen, Sarah L Sammons, Nancy U Lin, Ayal A Aizer |
| Journal | jnci cancer spectrum |
| Year | 2026 |
| DOI |
10.1093/jncics/pkag098
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.